

Mutation Detection in Neuronal Ceroid Lipofuscinoses 2 (*NCL2*) Gene in Egyptian Infants

A thesis

Submitted for the award of Ph.D. degree in Biochemistry

By

Miral Mahmoud Refeat Sherif

(M.Sc. in Biochemistry, 2009)

Supervised By

Prof. Dr. Amr Mahmoud Karim

Professor of Biochemistry
Faculty of Science
Ain Shams University

Prof. Dr. Alice Kamal Abd El Aleem

Professor of Human Molecular Genetics
Medical Molecular Department
Human Genetics and Genome Research Division
National Research Center

Prof. Dr. Mohamed Abdel Hady Ghazy

Professor of Biochemistry
Faculty of Science
Ain Shams University

**Biochemistry Department
Faculty of Science
Ain Shams University
2016**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا
مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة ، الآية ٣٢

Biography

Name : Miral Mahmoud Refeat Sherif

Date of : 1999

Graduation Biochemistry Department
Faculty of Science
Ain Shams University

Degree : B. Sc. in Biochemistry (good)
awarded

Grade : M. Sc. in Biochemistry

Occupation : Researcher assistant in Medical Molecular
Genetics Department, Human Genetics &
Genome Research Division, National
Research Center (NRC)

*This thesis has not been submitted
for publication at this or any other
university*

Miral Mahmoud Refeat

Contents

☉ Acknowledgement	
☉ List of Abbreviations	I
☉ List of Figures	IV
☉ List of Tables	VII
☉ Abstract	VIII
<hr/>	
☉ Introduction	1
☉ Aim of work	4
☉ Review of literature	5
1.1. Neuronal ceroid lipofuscinoses (NCLs)	5
1.2. Prevalence	5
1.3. Clinical Features	5
1.4. Genes associated with NCL Phenotypes	6
1.5. History	7
1.6. Classification of neuronal ceroid lipofuscinoses	7
1.7. The clinical spectrum of NCL diseases	9
1.7.1. Congenital onset NCL	9
1.7.2. Infantile onset NCL	10
1.7.2.1. CLN1 disease	10
1.7.2.2. CLN14 disease	11
1.7.3. Late-infantile onset NCL	11
1.7.3.1. CLN2 disease	12
1.7.3.2. CLN1 disease	13
1.7.3.3. CLN5 disease	13
1.7.3.4. CLN6 disease	14
1.7.3.5. CLN7 disease	14
1.7.3.6. CLN8 disease	15

Contents

1.7.4. Juvenile onset NCL	16
1.7.4.1. CLN3 disease	16
1.7.4.2. CLN1 disease	17
1.7.5. Adult onset NCL	18
1.7.5.1. CLN4 disease	18
1.7.5.2. CLN6 disease	18
1.7.5.3. CLN13 disease	19
1.7.5.4. CLN1 disease	19
1.7.5.5. CLN9 disease	19
1.8. The genetic spectrum of NCL diseases	20
1.8.1. Defects in lysosomal enzymes	21
1.8.1.1. Cathepsin D Protein	21
1.8.1.2. PPT1 Protein	22
1.8.1.3. TPP1 Protein	23
1.8.1.4. CLN13/CTSF protein	24
1.8.2. Transmembrane proteins	24
1.8.2.1. CLN3 Protein	24
1.8.2.2. CLN5 Protein	25
1.8.2.3. CLN6 Protein	26
1.8.2.4. MFSD8 Protein	27
1.8.2.5. CLN8 Protein	27

Contents

1.8.3. Other types	28
1.8.3.1. CLN4 disease	28
1.8.3.2. CLN9 disease	29
1.8.3.3. CLN11 disease	29
1.8.3.4. CLN12 disease	30
1.8.3.5. CLN14 disease	30
1.9. Strategy for the diagnosis of NCL types	31
1.9.1. Age of onset	31
1.9.2. Laboratory tests	32
1.9.2.1. Histological Findings	32
1.9.2.2. Enzyme Activity	33
1.9.2.3. Molecular Genetic Testing	34
1.9.2.3.1. DNA sequencing	34
1.10. Pathological diagnosis of the NCLS	37
1.10.1. Neuronal degeneration	37
1.10.2. Intracellular lipopigments	38

Contents

1.11. Mutation spectrum of NCL's disease	41
1.11.1. <i>CLN1/PPT1</i> Mutation Spectrum	44
1.11.2. <i>CLN2/TPPI</i> Mutation Spectrum	45
1.11.3. <i>CLN3</i> Mutation Spectrum	45
1.11.4. <i>CLN4</i> Mutation Spectrum	46
1.11.5. <i>CLN5</i> Mutation Spectrum	46
1.11.6. <i>CLN6</i> Mutation Spectrum	47
1.11.7. <i>CLN7/MFSD8</i> Mutation Spectrum	48
1.11.8. <i>CLN8</i> Mutation Spectrum	48
1.11.9. <i>CLN9</i> Mutation Spectrum	49
1.11.10. <i>CLN10/CTSD</i> Mutation Spectrum	49
1.11.11. Mutation Spectrum of other genes	49
1.12. Specialized palliative therapies in NCL	50
1.12.1. Therapies under Investigation	50
1.12.1.1. Gene therapy	51
1.12.1.2. Stem cell therapy	51
1.12.1.3. Enzyme replacement therapy (ERT)	51
1.12.1.4. Substrate reduction therapy	52
1.12.1.5. Other clinical trial	52